The safety of medicines taken during pregnancy often becomes a matter of public anxiety, especially when scientific evidence is misinterpreted or politicised. A new large-scale review published in The Lancet Obstetrics, Gynaecology and Women’s Health has brought much-needed clarity: paracetamol use during pregnancy does not increase the risk of autism, ADHD or intellectual disability in children. The findings decisively counter earlier speculative claims and reaffirm existing medical guidance.
Why the Paracetamol Debate Resurfaced?
The issue gained public attention after remarks by Donald Trump in September last year, which suggested a link between paracetamol intake during pregnancy and autism. These comments echoed concerns raised by earlier observational studies that reported weak associations between prenatal paracetamol exposure and neurodevelopmental disorders. However, those studies were limited by methodological flaws, including inadequate control for genetic and family-related factors.
What the Latest Lancet Review Examined
The new review is the most comprehensive assessment to date, analysing data from 43 studies and led by researchers from City St George’s, University of London. Crucially, it prioritised high-quality evidence and applied rigorous bias-assessment tools.
A key strength of the analysis was its focus on sibling-comparison studies. These studies compared siblings born to the same mother, where one pregnancy involved paracetamol use and another did not. This approach helps neutralise the influence of shared genetics, home environment and long-term parental characteristics—factors that conventional observational studies struggle to fully address.
What the Evidence Shows on Autism, ADHD and Disability
Across the sibling-comparison datasets:
- 262,852 children were assessed for autism,
- 335,255 for attention-deficit hyperactivity disorder (ADHD), and
- 406,681 for intellectual disability.
The results were consistent and clear. Compared to pregnancies with no paracetamol exposure, there was no increased risk of autism, ADHD or intellectual disability among children whose mothers used paracetamol during pregnancy. Researchers concluded that earlier reported associations were likely driven by underlying factors such as maternal fever, pain, or genetic predisposition rather than by the drug itself.
Understanding the Safety Profile of Paracetamol
Paracetamol, also known as acetaminophen, is the most commonly recommended analgesic and antipyretic during pregnancy worldwide. Its safety profile is considered more favourable than that of non-steroidal anti-inflammatory drugs (NSAIDs) or opioids, which are associated with well-documented risks to both the mother and the foetus. For this reason, paracetamol remains the first-line treatment for pain and fever in obstetric care when taken at recommended doses.
Why Avoiding Paracetamol Can Be Risky
Researchers caution that avoiding paracetamol altogether may unintentionally increase harm. Untreated fever during pregnancy is itself associated with adverse maternal and foetal outcomes. In this context, fear-driven avoidance of a safe and effective medication can create greater health risks than the medicine it seeks to avoid.
How Bias Was Addressed in the Study
All included studies were evaluated using the Quality In Prognosis Studies (QUIPS) tool, which systematically assesses risk of bias in research design, data collection and analysis. This strengthened confidence in the conclusions and helped establish the review as a gold-standard synthesis of existing evidence.
What This Means for Medical Guidelines
The findings reinforce current recommendations issued by major medical organisations across the world, including obstetric and gynaecological bodies. Clinicians emphasise that, when used appropriately, paracetamol remains a safe and essential option for managing pain and fever during pregnancy.
What to Note for Prelims?
- Paracetamol is the first-line analgesic and antipyretic recommended during pregnancy.
- The Lancet review found no causal link between prenatal paracetamol use and autism, ADHD or intellectual disability.
- Sibling-comparison studies help control for genetic and familial confounders.
What to Note for Mains?
- Importance of study design in public health research and avoiding causal overreach.
- Role of evidence-based medicine in countering misinformation.
- Balancing drug safety concerns with risks of untreated maternal conditions.
- Implications for health communication and public trust in medical guidance.